Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01879761 · ClinicalTrials.gov registry record
Immune Resolution After Staphylococcus Aureus Bacteremia
A clinical trial of Staphylococcus Aureus Infection and Immune Response To Sepsis, sponsored by University of Chicago.
- Active
- Registry status
- 102
- Enrollment target
- 1
- Study location
NCT01879761 is a study of Staphylococcus Aureus Infection and Immune Response To Sepsis that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 102 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01879761, a study of Staphylococcus Aureus Infection and Immune Response To Sepsis, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia. We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.
Conditions Studied
Study Locations (1)
Illinois
- University of Chicago Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-06 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01879761
The ClinicalTrials.gov registry entry for NCT01879761 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Staphylococcus Aureus Infection appearing as the primary indexed condition, and to 0 interventions.
NCT01879761 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT01879761 about?
NCT01879761 is a clinical study titled "Immune Resolution After Staphylococcus Aureus Bacteremia". The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia. We hypothesize that patients with prior immune dysfunction will have gr...
What is the current status of trial NCT01879761?
This trial is currently active not recruiting. The enrollment target is 102 participants. The study started on 2013-06. Estimated completion is 2026-06.
What conditions does trial NCT01879761 study?
This clinical trial studies the following conditions: Staphylococcus Aureus Infection, Immune Response To Sepsis.
Who is sponsoring clinical trial NCT01879761?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01879761 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Staphylococcus Aureus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.